A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Trial Profile

A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Tideglusib (Primary)
  • Indications Myotonic dystrophy
  • Focus Adverse reactions
  • Sponsors AMO Pharma
  • Most Recent Events

    • 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Oct 2017 According to an AMO Pharma media release, positive interim analysis of data from the first cohort of this trial were presented at the American Neurological Association's (ANA) 2017 Annual Meeting.
    • 25 Sep 2017 According to an AMO Pharma media release, data from the study will be presented at the American Neurological Association's (ANA) 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top